Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM9HPW3)

• Drug Name: Exemestane Drug Info
• Synonyms: Aromasil; Aromasin; Aromasine; EXE; Exemestance; Exemestano; Exemestanum; Nikidess; Pfizer brand of exemestane; Curator_000009; Fce 24304; Aromasin (TN); Aromasin, Exemestane; Exemestano [INN-Spanish]; Exemestanum [INN-Latin]; FCE-24304; PNU-155971; Exemestane [USAN:INN:BAN]; Exemestane (JAN/USP/INN); (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; 6-Methylenandrosta-1,4-diene-3,17-dione; 6-Methyleneandrosta-1,4-diene-3,17-dione; 6-methylideneandrosta-1,4-diene-3,17-dione
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 60198
  ChEBI ID: CHEMBL1200374
  CAS Number: CAS 107868-30-4
  TTD Drug ID: D0D2VS
  INTEDE Drug ID: DR0675
  ACDINA Drug ID: D00261

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Glutathione metabolism	2.23	0.00e+0	43/57 (75.44%)	GCLM;GPX3;GCLC;...
Steroid hormone biosynthesis	2.07	0.00e+0	43/61 (70.49%)	AKR1C2;AKR1C1;CYP1B1;...
Complement and coagulation cascades	2.01	0.00e+0	76/85 (89.41%)	C1QB;C1QA;SERPING1;...
PPAR signaling pathway	1.94	1.98e-3	66/74 (89.19%)	ME1;ACSL1;NR1H3;...
Ascorbate and aldarate metabolism	1.90	6.34e-3	15/30 (50%)	UGDH;ALDH3A2;ALDH2;...
Metabolism of xenobiotics by cytochrome P450	1.89	5.28e-3	49/77 (63.64%)	AKR1C1;CYP1B1;ALDH3A1;...
Arachidonic acid metabolism	1.86	6.79e-3	48/61 (78.69%)	AKR1C3;GPX3;PLA2G2A;...
Proteasome	1.85	6.94e-3	44/46 (95.65%)	PSMD12;PSMA4;PSMB2;...
Folate biosynthesis	1.78	1.85e-2	23/26 (88.46%)	AKR1B10;AKR1C3;MOCOS;...
Ribosome biogenesis in eukaryotes	1.77	1.90e-2	52/108 (48.15%)	HEATR1;POP7;TBL3;...
Staphylococcus aureus infection	1.76	1.87e-2	72/95 (75.79%)	C1QB;C1QA;KRT15;...
Drug metabolism	1.73	2.18e-2	78/151 (51.66%)	ALDH3A1;TYMP;MAOA;...
Fatty acid degradation	1.73	2.01e-2	40/43 (93.02%)	ACSL1;ADH1B;ALDH3A2;...
Pentose and glucuronate interconversions	1.64	4.64e-2	17/34 (50%)	AKR1B10;UGDH;UGT2B4;...
Phenylalanine metabolism	1.63	4.86e-2	14/17 (82.35%)	ALDH3A1;MAOA
Retinol metabolism	1.63	4.56e-2	41/68 (60.29%)	ADH1B;ALDH1A3;AOX1;...
Other glycan degradation	-1.83	4.28e-2	13/18 (72.22%)	MAN2B1;MANBA;NEU1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H, 48H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.04uM - 10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 2.22uM	24H	Show ▼